Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesOther Gross PP&E Adjustments
Ratios

RedHill Biopharma (RDHL) EBIAT (2016 - 2023)

Historic EBIAT for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to $101.2 million.

  • RedHill Biopharma's EBIAT rose 29186.8% to $101.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was -$40.0 million, marking a year-over-year increase of 7561.85%. This contributed to the annual value of -$8.3 million for FY2024, which is 13457.1% down from last year.
  • As of Q2 2023, RedHill Biopharma's EBIAT stood at $101.2 million, which was up 29186.8% from -$50.2 million recorded in Q1 2023.
  • RedHill Biopharma's EBIAT's 5-year high stood at $101.2 million during Q2 2023, with a 5-year trough of -$145.2 million in Q4 2021.
  • Over the past 5 years, RedHill Biopharma's median EBIAT value was $11.1 million (recorded in 2019), while the average stood at -$4.2 million.
  • As far as peak fluctuations go, RedHill Biopharma's EBIAT tumbled by 106284.39% in 2021, and later surged by 29186.8% in 2023.
  • RedHill Biopharma's EBIAT (Quarter) stood at $11.8 million in 2019, then grew by 27.44% to $15.1 million in 2020, then tumbled by 1062.84% to -$145.2 million in 2021, then surged by 52.14% to -$69.5 million in 2022, then surged by 245.63% to $101.2 million in 2023.
  • Its EBIAT stands at $101.2 million for Q2 2023, versus -$50.2 million for Q1 2023 and -$69.5 million for Q4 2022.